New Mono-Focal and Accommodating IOLs are Designed to Help Surgeons Treat Cataracts with Enhanced Precision and Predictability
St. Petersburg, Florida – April 20, 2006 – Lenstec, Inc, — a provider of technologically- advanced lenses for treating vision disorders – today announced the introduction of its Precision Series™ intraocular lens implants (IOLs) for treating patients with cataracts.
Based on the company’s proprietary lens manufacturing technology, these premium lenses are designed to improve predictability in cataract surgery by reducing the variability (i.e., tolerance or margin of error) inherent in any manufactured lens. They reduce variability, measured as the difference between a lens’ labeled prescription and its actual power, up to 300 percent compared to other cataract replacement lenses manufactured in accordance with less stringent ISO standards.
In addition, Lenstec’s high precision manufacturing process makes it possible to produce lenses in 0.2D to 0.25D increments, compared to the standard 0.5D increments offered by other IOL manufacturers. As a result, surgeons are afforded a greater choice of lenses, which helps them tailor treatment more precisely for each patient.
“Our new Precision Series greatly reduces lens variability, which is one of the leading causes of refractive error when it comes to treating cataract patients,” said Lenstec Vice President Jim Simms.
William F. Maloney, M.D., associate clinical professor at UC Irvine, recently warned surgeons about the problems associated with such lens variability. “The IOL label itself is now likely to be the greatest source of refractive error in your surgery. When it comes to power, what you see is definitely not what you get. The tolerance for error in most IOL labeling is now obsolete, and it too fails today’s refractive accuracy test. Until that changes, your efforts at refractive recalibration will be hostage to this outdated industry standard” (Maloney W., Ocular Surgery News, Sept. 2005).Lenstec’s Precision Series includes the Softec PS™ mono-focal lens and the Tetraflex™ presbyopic accommodating lens, which is designed to provide cataract and presbyopia patients with seamless clear near, intermediate and far vision. The Softec PS is available in 0.25D steps, with a tolerance of 0.125D. The Tetraflex is available in 0.2D steps, with a tolerance of 0.10D. The Tetraflex lens is currently in clinical trials in the U.S., while the Softec lens is awaiting IDE status.
Intraocular lens implants (IOLs) are used to treat cataracts – a vision disorder characterized by cloudy or opaque areas in the eye’s natural lens that usually develop gradually with advancing age (environmental factors, metabolic diseases and certain medications can also accelerate cataract formation). Cataract surgery involves replacing the eye’s damaged lens with an implantable IOL. Accommodating IOLs such as Lenstec’s Tetraflex are designed to treat both cataracts and presbyopia, which is the progressive, age-related loss of the eye’s ability to focus for reading and other close tasks.
An estimated 2.5 million people annually in the U.S. undergo cataract surgery with an IOL implant, and an estimated 10-15 million IOLs are implanted worldwide each year.
Lenstec, Inc. is a leading provider of medical devices used by ophthalmic surgeons to treat vision disorders. The company designs, manufacturers and distributes a wide range of intraocular lens (IOL) implants and lens injection systems, including the industry-leading SoftecHD IOL, Tetraflex presbyopic IOL and Precision Series™ IOLs. Proprietary lens manufacturing technology enables the company to produce premium lenses with reduced variability and improved surgical predictability. Founded in 1992, Lenstec is dedicated to advancing possibilities for ophthalmic surgeons and their patients worldwide.